Soft tissue injuries are genuinely hard to heal. Tendons, ligaments, and cartilage have poor blood supply and limited regenerative capacity, which is why a shoulder can keep catching or an Achilles can keep flaring long after rest, physical therapy, and even a cortisone shot or two. That difficulty is part of why two peptides, BPC-157 and TB-500, keep coming up in conversations about joint pain and recovery. Both have drawn real scientific interest, with laboratory research studying their possible role in tissue repair. Neither is FDA-approved for this use, and the human evidence is thin. This article lays out what the research actually shows, where the honest limits are, and how to find safe, legal treatment if you decide to pursue it.
Why joint and soft tissue injuries are hard to heal
Tendons, ligaments, and cartilage are low-vascular tissues, meaning they receive relatively little blood flow. Blood carries the nutrients and repair cells that healing depends on, so tissues that get less of it tend to recover slowly and incompletely. This is the basic problem researchers point to when they study whether a compound might support the repair process. It is also why symptom-focused options like anti-inflammatories can mask discomfort without addressing the underlying structure.
What BPC-157 is
BPC-157 (body protection compound-157) is a synthetic peptide based on a 15-amino-acid sequence identified in gastric juice. In animal studies it has been examined for effects on tissue repair, including the formation of new blood vessels (angiogenesis), signaling in tendon fibroblasts, and collagen synthesis. Researchers describe these as the mechanisms they are investigating, not proven outcomes in people. BPC-157 is not FDA-approved, and it is worth knowing that it does not appear on the FDA's list of bulk substances eligible for compounding, which affects how and whether a licensed pharmacy can supply it.
What TB-500 is
TB-500 is a synthetic form related to thymosin beta-4, a peptide the body produces naturally and that is present in wound fluid. Laboratory research has looked at its possible role in cell migration (through a process called actin polymerization), inflammatory signaling, and tissue remodeling. Thymosin beta-4 itself has been studied more broadly for wound healing, including some early clinical work in skin ulcers. As with BPC-157, TB-500 is investigational and not FDA-approved for musculoskeletal use.
Why the two are often discussed together
BPC-157 and TB-500 are studied for what researchers describe as distinct but complementary pathways: one is examined mostly for local vascular and fibroblast activity, the other for broader cell migration and inflammatory signaling. That pairing sometimes comes up in discussion, but it is important to be clear that the combination has not been validated in controlled human trials. The rationale is mechanistic, not proven.
What the research actually shows
The most important thing to understand is that the strongest evidence for both peptides comes from animal models and cell studies. Large randomized controlled trials in humans for tendon, ligament, or cartilage healing do not exist. That is a real limitation, and any source that describes these peptides as proven treatments is overstating the case.
A 2019 review in Cell and Tissue Research reported that studies of BPC-157 in animal models described positive healing effects across several soft tissues, including tendon, ligament, and skeletal muscle. Other laboratory work has examined how BPC-157 affects tendon cell outgrowth, survival, and migration, and one animal study looked at muscle healing that had been impaired by corticosteroids. For thymosin beta-4, research has reported faster skin wound healing in animal models, and a couple of early Phase 2 trials examined its effect on ulcers in patients. None of this establishes that either peptide heals joints in humans. It suggests the biological signals researchers are interested in are real enough to keep studying.
How peptides compare to cortisone, PRP, and stem cell procedures
People considering peptides have usually looked at the more established options first. An honest comparison helps.
Cortisone injections
Corticosteroids are well-established anti-inflammatory injections, and the clinical evidence supports their use for short-term pain relief; they are widely covered by insurance. The trade-off is that cortisone is understood to suppress inflammation rather than repair tissue, and repeated injections have been associated in the literature with tendon weakening and cartilage changes. It is generally described as a symptom-management tool, not a tissue-healing strategy.
Platelet-rich plasma (PRP)
PRP concentrates a patient's own platelets and growth factors and injects them at the injury site. There is a growing evidence base for certain conditions, and it uses your own biology, but reported results vary with preparation technique and provider, it is typically cash-pay in the hundreds to low thousands of dollars per injection, and it often requires multiple sessions.
Stem cell procedures
Stem cell injections are marketed for regenerative potential but carry highly variable reported outcomes and high cash-pay costs. The FDA has taken enforcement action against clinics making unsubstantiated stem cell claims, and the evidence base for musculoskeletal use is still emerging. Cost and evidence both warrant caution.
The peptides in this discussion differ from all three in a key way: their evidence is largely preclinical. They are not a proven alternative to these procedures. They are compounds under investigation.
Legality, sourcing, and safety
This is where the most important distinctions live. There is a real difference between a licensed 503A or 503B compounding pharmacy dispensing a peptide against a valid prescription and a "research use only" product sold online outside the pharmacy system. The Peptide Foundation excludes the latter entirely. Gray-market peptides sold for "research" carry no guarantee of sterility, identity, or accurate contents, and reporting has documented the health concerns around this booming unregulated market.
It also matters which peptide you are talking about. Some peptides can be compounded by licensed pharmacies under a prescription; others, including BPC-157, are not on the FDA's list of substances eligible for compounding, which limits legitimate access. Neither BPC-157 nor TB-500 is FDA-approved. Reported side effects in the available studies have generally been mild and local, but the safety data in humans is limited, and pro-angiogenic effects raise theoretical concerns that make medical evaluation important, particularly for anyone with a history of cancer or who is pregnant. Self-sourcing and self-administering is exactly the scenario the Foundation warns against.
How to find safe, legal treatment
If you want to explore peptides responsibly, the path runs through a licensed clinician and a licensed pharmacy, never a research-chemical website. The Foundation exists to make that easier to evaluate. Start with the provider directory to find clinicians who work within the licensed pharmacy system, and read how we rate to understand what we score providers on and why we take no money from the ones we rate. If you are weighing your options, our FAQ covers common questions about legality, sourcing, and what "investigational" actually means.
The honest bottom line
BPC-157 and TB-500 are being studied for joint pain and soft tissue recovery, and the early animal research is interesting enough to explain the attention. That is not the same as proof. These are investigational compounds, not approved treatments, and the human evidence has not caught up to the enthusiasm. If you pursue them, do it through a licensed provider and a licensed pharmacy, keep your expectations tied to what the evidence actually supports, and treat any source promising guaranteed results as a red flag rather than a recommendation.